The overall goal of this project is to test the feasibility of performing real-time electrogram morphology recurrence (EMR) mapping in patients with persistent atrial fibrillation (AF) to locate areas of high electrogram morphology recurrence rate. The Investigator believe that the EMR mapping can be integrated into cardiac mapping and used to identify potential sites for ablation. Furthermore, this study could help demonstrate the efficacy of this technology's ability to terminate or slow AF. The Investigator will test this technology on ten subjects undergoing a second ablation procedure. The Investigator will map the AF utilizing the EMR to indicate locations of stable activity and ablate the area. The Investigator believes that the study could produce acute AF termination or AF cycle length slowing. In addition to testing the real-time electrogram morphology recurrence mapping, the study would also like to determine the acute effects of radiofrequency ablation of areas of high recurrence rates and determine long term freedom from AF following ablation of areas of high recurrence rates.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Fifteen second AF recordings will be made using a multipolar electrode catheter to map the entire right atrium \& then the left atrium.
University of Miami
Miami, Florida, United States
Real-time Electrogram Morphology Recurrence (EMR) Mapping Feasibility
As measured by number of patients where real-time EMR mapping is completed.
Time frame: 2 hours
Ablation Acute Effects
ablation based on EMR map as measured by number of participants that terminate atrial fibrillation.
Time frame: 2 hours
Number of Participants With Treatment Emergent Adverse Events
Number of participants with treatment emergent adverse events will be measured by the type of adverse event, severity, and whether the AE/SAE is related to the mapping
Time frame: 30 days
Ablation Acute Effects
ablation based on EMR map as measured by number of participants that slow atrial fibrillation cycle length by at least 15%.
Time frame: 2 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.